.avif)
TMPRSS2:ERG Fusion Test - Prostate Cancer Biomarker
Detects the TMPRSS2:ERG gene fusion—a common prostate cancer biomarker—to help identify men at risk of clinically significant prostate cancer. When used with other clinical tests, it can improve risk stratification and help avoid missed cancers, unnecessary biopsies, and overtreatment.
Oncotype DX Test - 17-Gene Prostate Cancer Biomarker
Oncotype DX is a genomic assay that analyzes tumor gene expression—primarily in early‑stage breast cancer (including DCIS)—to predict recurrence risk and the likely benefit of chemotherapy. By clarifying recurrence risk and chemo benefit, it helps patients and clinicians personalize care and avoid unnecessary chemotherapy and its side effects.
BRCA2 Gene Test - Prostate Cancer Biomarker
A BRCA2 gene test detects inherited variants that substantially raise lifetime risk of breast and ovarian cancer (and also increase risks of pancreatic, male breast, and certain prostate cancers). Knowing your BRCA2 status lets you pursue enhanced screening and targeted risk‑reduction options (surveillance, preventive treatments or surgery) to detect cancer earlier or lower your chance of advanced disease.
Prolaris Test - 46-Gene Prostate Cancer Biomarker
Prolaris is a genomic test that measures tumor cell‑cycle activity to predict how aggressive a prostate cancer is and the risk it will progress or recur. Its results can help guide treatment decisions—potentially avoiding unnecessary surgery or radiation for low‑risk disease and identifying cancers that need timely, aggressive therapy to reduce the chance of advanced prostate cancer.
PSA Test - Prostate Cancer Biomarker
A PSA (prostate-specific antigen) blood test screens for elevated PSA levels that can indicate prostate cancer or other prostate conditions such as benign prostatic hyperplasia and prostatitis. Early detection through PSA testing can prompt timely evaluation and treatment, helping reduce the risk of advanced disease and complications.
AR-V7 Test - Prostate Cancer Biomarker
Detects the AR‑V7 androgen‑receptor splice variant in circulating tumor cells to predict likely resistance to AR‑targeted therapies (e.g., enzalutamide, abiraterone). Knowing your AR‑V7 status can help you avoid ineffective hormone treatments and their side effects, enabling faster transition to more appropriate therapy and reducing risk of disease progression.
Free PSA Test - Prostate Cancer Biomarker
This free PSA test screens prostate health by measuring PSA levels and the free/total PSA ratio to detect early signs of prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis. Early detection enables timely follow-up and treatment to reduce the risk of advanced disease and more invasive interventions.
Prostate Health Index (PHI) - Prostate Cancer Biomarker
The Prostate Health Index (PHI) is a blood test that combines total PSA, free PSA and [-2]proPSA into a single score to better assess a man’s risk of clinically significant prostate cancer. By improving detection of aggressive disease and reducing false positives, PHI can help men avoid unnecessary biopsies and overtreatment while catching cancers earlier when they’re more treatable.
BRCA1 Gene Test - Prostate Cancer Biomarker
This BRCA1 gene test screens for inherited variants that substantially raise lifetime risk of breast and ovarian cancer (and can also affect prostate, pancreatic, and male breast cancer risk). Knowing your BRCA1 status can help you and your healthcare provider begin earlier surveillance, risk‑reducing strategies, or targeted treatments that may lower your chances of advanced cancer.
PCA3 Urine Test - Prostate Cancer Biomarker
A non‑invasive urine test that measures PCA3 gene overexpression to help identify men at higher risk of prostate cancer and guide whether a biopsy is needed. By improving diagnostic accuracy over PSA alone, it can help avoid unnecessary invasive biopsies and enable earlier detection of prostate cancer.
.svg)
